Astellas’ Mycamine(R) (micafungin) Licensed For Use In Europe To Treat Serious Fungal Infections

The European Medicines Agency (EMEA) has announced the marketing authorisation of Mycamine®, Astellas Pharma Europe’s treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Mycamine® will initially be available in the U.K and across the European market shortly after this.

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on May 15th, 2008